Indeed, we also found higher levels of GM-CSF to be associated with higher tumor burden in the anti-PD-1-treated mice from the E0771/4T1 study, pointing to a possible pro-tumorigenic GM-CSF-dependent cascade driven by the 4T1 cohort. The gene discussed is PDCD1; the disease is neoplasm.